- |||||||||| letrozole / Generic mfg.
Journal: Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy. (Pubmed Central) - Jan 22, 2023 However, despite the promising findings reported by several studies, to date Letrozole is not yet officially mentioned in the guidelines for "Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome". In this scenario, the current study discusses Letrozole approaches scientifically available to prevent OHSS.
- |||||||||| letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women. (Pubmed Central) - Jan 22, 2023 P1 No subject demonstrated signs of drug induced liver injury and no subject showed serum folate level outside the normal range. Hence, our data suggests that a daily dose of 800 mg of EGCG alone or in combination with clomiphene citrate or letrozole (for 5 days) is well-tolerated and is not associated with liver toxicity or folate deficiency in reproductive-aged women.
- |||||||||| Ibrance (palbociclib) / Pfizer
Trial completion date, Metastases: INGE-B: Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (clinicaltrials.gov) - Jan 19, 2023 P2, N=388, Active, not recruiting, HighlightsThe strong relationship between obesity, insulin resistance, and polycystic ovarian syndrome.Disturbance of the PI3K/Akt signaling pathway is involved in the progression of polycystic ovary syndrome-insulin resistance (PCOS-IR).In PCOS-IR rats, combined SeNPs and metformin therapy considerably alleviated IR by acting on the PI3K/Akt signaling pathway.The combination of SeNPs and metformin clearly repaired ovarian polycystic pathogenesis and improved hormonal imbalance in PCOS-IR rats. Trial completion date: Jan 2023 --> Dec 2023
- |||||||||| letrozole / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Letrozole in Induction of Abortion of Anembryonic Pregnancy (clinicaltrials.gov) - Jan 18, 2023 P=N/A, N=96, Completed, Trial completion date: Sep 2022 --> Sep 2023 Recruiting --> Completed | Trial completion date: May 2022 --> Jan 2022 | Trial primary completion date: May 2022 --> Jan 2022
- |||||||||| letrozole / Generic mfg.
Journal: Live birth associated with peak serum estradiol concentrations in letrozole intrauterine insemination (IUI) cycles. (Pubmed Central) - Jan 13, 2023 In letrozole ovulation induction cycles followed by intrauterine insemination, lower LBR and clinical pregnancy rates were found in women with lower E2 concentrations compared with higher E2 concentrations at the 25, 50, and 75 percentile E2 concentration quartiles. Where possible, delaying HCG trigger until E2 concentration rises following aromatase inhibition and approaches physiologic periovulatory concentration may improve pregnancy rates with letrozole followed by intrauterine insemination.
- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Journal: Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2HR breast cancer. (Pubmed Central) - Jan 6, 2023 P2 Furthermore, CALML5 was revealed to be a risk factor in the treatment of HER2/HR breast cancer and the usage of dalpiciclib might overcome the drug resistance to pyrotinib + tamoxifen due to CALML5 expression. Our study provided evidence that the usage of dalpiciclib in the treatment of HER2/HR breast cancer could partially abrogate the estrogen signaling pathway activation caused by anti-HER2 therapy and revealed that CALML5 could serve as a risk factor in the treatment of HER2/HR breast cancer.
- |||||||||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date: POETIC-A: PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (clinicaltrials.gov) - Dec 21, 2022 P3, N=2500, Recruiting, This observation is of both clinical and pathophysiological relevance, also in view that the identification of molecular determinants and cellular pathways implicated in Lp(a) synthesis and metabolism is still of concern as a critical issue in lipidology and CV prevention. Trial completion date: Sep 2028 --> Mar 2032 | Trial primary completion date: Mar 2026 --> Sep 2030
|